1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Tibet Cheezheng Tibetan Medicine Co., Ltd. Class A

Tibet Cheezheng Tibetan Medicine Co., Ltd. Class A

SSZSE:002287
19.31
CNY
+0.29
(+1.52%)
1.58EPS
11.92P/E
10.78BMarket Cap
Tibet Cheezheng Tibetan Medicine Co., Ltd. Class A
SZSE:002287
(Shenzhen Stock Exchange)

Recent

price

19.31

P/E

ratio

11.92

div

yld

2.28%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.99
1.5
1.78
1.85
1.82
1.89
1.84
2
2.3
2.65
2.81
3.35
3.86
3.86
4.41
4.45
4.75
Revenue per Share
0.32
0.32
0.36
0.41
0.45
0.5
0.55
0.57
0.6
0.69
0.76
1.35
0.89
1.1
1.1
1.19
1.58
Basic EPS, GAAP
0.08
-0.19
0.21
0.24
0.44
0.37
0.4
0.31
0.7
0.67
-0.19
1.72
0.03
0.87
0.38
1.06
- -
Free Cash Flow per Basic Share
0.24
0.22
0.22
0.24
0.27
0.3
0.32
0.31
0.33
0.32
0.37
0.37
0.64
0.42
0.53
0.83
0.44
Dividend per Share
2.25
2.36
2.51
2.67
2.85
3.06
3.29
3.56
3.85
4.24
4.94
5.98
6.29
7.02
7.65
8.65
8.91
Book Value per Share
2.21
2.22
2.36
2.53
2.69
2.89
3.19
3.47
3.76
4.15
4.61
5.22
5.58
6.35
7.04
8.12
8.4
Tangible Book Value per Share
527
528
525
523
523
527
527
527
527
528
529
529
530
530
530
544
556
Basic Weighted Avg Shares
524
789
934
969
950
995
968
1,053
1,213
1,403
1,485
1,770
2,045
2,045
2,338
2,416
2,643
Sales/Revenue/Turnover
27.54
23.34
21.33
23.13
24.72
25.23
25.99
29.88
26.44
26.27
28.42
28.12
29.43
30.96
26.16
30.2
36.47
Operating Margin (%)
9
12
16
24
25
33
30
23
23
36
44
66
83
93
139
142
- -
Depreciation Expense
170
171
190
213
238
265
290
301
319
364
404
716
473
581
582
648
879
Net Income, GAAP
1.92
15.91
15.73
18.12
17.69
10.3
8.28
7.18
9.39
9.19
9.17
9.78
9.55
10.12
10.04
12.48
11.77
Effective Tax Rate (%)
32.55
21.63
20.36
22.01
25
26.63
29.93
28.57
26.27
25.97
27.2
40.43
23.11
28.42
24.91
26.84
33.25
Profit Margin (%)
1,065
1,016
1,075
1,125
1,181
1,041
1,128
1,219
1,287
1,481
2,202
1,628
1,832
1,949
2,490
2,630
2,635
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
911
841
934
1,068
799
7
28
LT Debt
1,209
1,278
1,352
1,448
1,550
1,651
1,751
1,894
2,045
2,262
2,635
3,220
3,388
3,770
4,113
4,996
5,145
Total Equity
12.74
13.13
13.21
12.98
12.79
14.44
13.68
14.92
15.27
15.59
12.75
16.58
9.59
11.02
10.49
11.33
14.84
Return on Invested Capital (%)
14.47
12.99
13.96
14.75
15.78
16.15
16.16
15.3
15.8
15.99
13.21
18.03
10.79
12.32
11.43
11.69
15.04
Return on Capital (%)
14.63
14.04
14.82
15.63
16.31
17.01
17.33
16.66
16.32
17.04
16.61
24.74
14.53
16.47
14.96
14.39
19.28
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
923
777
889
LT Borrowings
3
28
25
LT Finance Leases
3
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
572
572
572
Market Capitalization
13,536
13,153
10,779

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,308
4,067
3,963
Cash, Cash Equivalents & STI
2,948
2,655
2,849
Accounts Receivable, Net
100
242
377
Inventories
294
340
329
Total Current Liabilities
1,679
1,305
1,327
Payables & Accruals
- -
- -
- -
ST Debt
923
777
889
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.85%
13.85%
21.45%
Free Cash Flow
236.83%
477.71%
186.44%
Net Income, GAAP
12.21%
15.55%
11.36%
Sales/Revenue/Turnover
9.52%
10.48%
3.34%
Total Cash Common Dividend
15.07%
25.75%
60.4%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
365
645
462
866
2,338
2025
403
772
- -
893
2,416
2026
405
573
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.43
0.13
0.36
1.1
2025
0.14
0.53
- -
0.4
1.19
2026
0.17
0.49
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.51
0.01
0.53
2025
0.22
- -
- -
- -
0.83
2026
0.01
0.41
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Tibet Cheezheng Tibetan Medicine Co., Ltd. (002287.SZ) engages in the research, development, production, and sale of Tibetan medicines in China. The company offers a range of products including emplastrum such as Cheezheng Xiaotong pain relieving plaster; ointments including Qingpeng Ointment and Baimai Ointment (White Veil Ointment); granules and capsules such as Shiwei Gentian flower granules and capsules, Renqing Mangjue capsules; oral medicines including Ruyi Jumbo tablets and Safflower Ruyi pills; and crude drugs, targeting orthopedics, neurology, dermatology, gynecology, pediatrics, respiratory, gastroenterology, cardiovascular, cerebrovascular, musculoskeletal, digestive, urinary, and reproductive systems. It distributes these products primarily within the domestic Chinese market with limited overseas sales to regions including the United States, Canada, Hong Kong, Malaysia, Singapore, and South America. Founded in 1995 and headquartered in Nyingchi, Tibet Autonomous Region, China, the company operates as a subsidiary of Gansu Qizheng Industry Group Co., Ltd. and maintains 22 wholly-owned and holding subsidiaries, including GMP-certified pharmaceutical factories and GSP marketing firms, employing approximately 3,170 people. In recent developments, the company announced an equity buyback plan in March 2025 for up to CNY 160 million, with tranche updates through July 2025; reported earnings for the half-year ended June 30, 2025 in July; and approved an external investment project at its board meeting on July 31, 2025, funded by internal resources over a two-year construction period.